Trial intelligence / Profile preview

Visilizumab in intravenous steroid-refractory ulcerative colitis

2005-002063-87Phase 2Completed

Sponsor
PDL BioPharma
Start
Nov 2005
Modality
Small Molecules
Countries
1
01

Overview

Phase 2, randomised, double-blind trial of iron sucrose in autoimmune colitis (2 arms), sponsored by PDL BioPharma. Primary endpoint: Clinical response at Day 45. Started Nov 2005; status: completed.

02

Drugs

iron sucrose
03

Conditions

autoimmune colitis

Beyond the preview

Go deeper on 2005-002063-87.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2005-002063-87.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call